Malta - English - Medicines Authority

curium international boulevard bischoffsheim 39 boîte 4 1000 bruxelles , belgium - fludeoxyglucose - solution for injection - fludeoxyglucose 185 mbq/ml - diagnostic radiopharmaceuticals

Malta - English - Medicines Authority

iason gmbh feldkirchner str. 4, a-8054 graz, austria - fludeoxyglucose - solution for injection - fludeoxyglucose 1 gigabecquerel/millilitre - diagnostic radiopharmaceuticals

Malta - English - Medicines Authority

iason gmbh feldkirchner str. 4, a-8054 graz, austria - fludeoxyglucose - solution for injection - fludeoxyglucose 1 gigabecquerel/millilitre - diagnostic radiopharmaceuticals

Ireland - English - HPRA (Health Products Regulatory Authority)

m2i limited - fludeoxyglucose (18f) - solution for injection - 1-13 gbq/ml

United States - English - NLM (National Library of Medicine)

petnet solutions, inc. - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 200 mci in 1 ml - fludeoxyglucose f 18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none. risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose

Ireland - English - HPRA (Health Products Regulatory Authority)

curium pharma ireland limited - fludeoxyglucose [18f] - solution for injection - 110-10,000 megabecquerel(s)/millilitre - other diagnostic radiopharmaceuticals for tumour detection; fludeoxyglucose (18f)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

radboud translational medicine b.v. - fludeoxyglucose (18 f) 200 mbq/ml - solution for injection - 200 mbq/ml - fludeoxyglucose (f-18) 200 mbq/ml - fludeoxyglucose (18f)

United States - English - NLM (National Library of Medicine)

the methodist hospital research institute - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 0.3 ci in 1 ml - fludeoxyglucose f18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection usp crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiatio

United States - English - NLM (National Library of Medicine)

trustees of the university of pennsylvania - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 200 mci in 1 ml - fludeoxyglucose f18 injection is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none. pregnancy category c. animal reproduction studies have not been conducted with fludeoxyglucose f 18 injection. it is also not known whether fludeoxyglucose f 18 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. consider alternative diagnostic tests in

United States - English - NLM (National Library of Medicine)

precision nuclear, llc - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 500 mci in 1 ml - fludeoxyglucose f 18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation d